FDA Approved Semaglutide Injection to Reduce Risk of Serious Heart Problems in Overweight Adults

On March 8, 2024, The U.S. FDA has approved Wegovy (semaglutide) injection, a weight management medication also designed to reduce the risk of major cardiovascular events in overweight adults with a history of cardiovascular disease. This addresses a crucial health issue affecting roughly 70% of American adults who are overweight or obese, thereby increasing their risk for heart disease and stroke. 

Recommended Courses:  

The approval comes after a clinical trial involving over 17,600 participants showed that Wegovy significantly reduced the occurrence of adverse cardiovascular outcomes. However, this medication carries a serious warning for thyroid C-cell tumors and several other potential side effects, making it unsuitable for certain patients.  

Wegovy, which is to be used in conjunction with a modified diet and increased physical activity, is a significant step in public health and offers a new treatment pathway, especially relevant for nurses and practitioners dealing with patients battling obesity and heart conditions. Available through Novo Nordisk A/S, Wegovy cannot be combined with other semaglutide-containing entities or similar GLP-1 receptor antagonists.